Earnings ·
Schrödinger reported second quarter 2026 financial results with total revenue of $58.9 million, an 8% increase…
SDGRSchrodinger, Inc.
Schrödinger reported second quarter 2026 financial results with total revenue of $58.9 million, an 8% increase year-over-year. Annual contract value (ACV) reached $29.6 million, reflecting 27% growth, while software revenue declined 10% to $32.5 million due to a transition to hosted licensing. Drug discovery revenue rose to $23.0 million, driven by a $10 million milestone from the Ajax Therapeutics acquisition. The company reported net income of $6.0 million compared to a net loss of $43.2 million in the prior year period, aided by a $45.9 million gain on equity investments linked to Eli Lilly’s acquisition of Ajax Therapeutics. Operating expenses decreased 6% to $74.0 million. The company raised its full-year drug discovery revenue guidance to $65–$75 million and expects ACV growth of 10–15%. Schrödinger operates in the biotechnology software industry, providing computational platforms for molecular discovery and drug development.